Abstract
Intrinsic arterial myogenic function comprises the degree of constriction (myogenic tone), the arterial constriction to an increase in intraluminal pressure and vice versa (myogenic response), and forced dilation at high intraluminal pressure. Although the development of myogenic tone at 40-60 mmHg involves the influx of calcium (Ca2+) through voltage- dependent Ca2+ channels and an elevation in arterial intracellular Ca2+ (Ca2+ i), myogenic responses between 60-140 mmHg involves predominantly Rho kinase (ROK)-mediated changes in Ca2+ sensitivity. In the cerebral circulation an impaired myogenic response results in impaired cerebral autoregulation and susceptibility hypertension-induced cerebral haemorrhage. An impaired cerebral artery myogenic response, due to blunted ROK mediated changes in Ca2+ sensitivity, may be a consequence of defective mechanotransduction of the intraluminal pressure stimulus; this may be a result of abnormalities in the extracellular matrix. In the coronary circulation distinctions between the mechanisms involved in the development of myogenic tone and the myogenic response have not been clearly defined. However, coronary artery myogenic tone is dependent on both Ca2+ entry through voltage –dependent Ca2+ channels and protein kinase C (PKC) activity. Impaired coronary myogenic tone has been observed in animal models of disease but the implications of these findings are currently uncertain.
Keywords: Autoregulation, cerebral haemorrhage, cerebral arteries, coronary arteries, in vitro studies, myogenic response, SHRSP.
Current Vascular Pharmacology
Title:Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Volume: 12 Issue: 6
Author(s): Ashley S. Izzard and Anthony M. Heagerty
Affiliation:
Keywords: Autoregulation, cerebral haemorrhage, cerebral arteries, coronary arteries, in vitro studies, myogenic response, SHRSP.
Abstract: Intrinsic arterial myogenic function comprises the degree of constriction (myogenic tone), the arterial constriction to an increase in intraluminal pressure and vice versa (myogenic response), and forced dilation at high intraluminal pressure. Although the development of myogenic tone at 40-60 mmHg involves the influx of calcium (Ca2+) through voltage- dependent Ca2+ channels and an elevation in arterial intracellular Ca2+ (Ca2+ i), myogenic responses between 60-140 mmHg involves predominantly Rho kinase (ROK)-mediated changes in Ca2+ sensitivity. In the cerebral circulation an impaired myogenic response results in impaired cerebral autoregulation and susceptibility hypertension-induced cerebral haemorrhage. An impaired cerebral artery myogenic response, due to blunted ROK mediated changes in Ca2+ sensitivity, may be a consequence of defective mechanotransduction of the intraluminal pressure stimulus; this may be a result of abnormalities in the extracellular matrix. In the coronary circulation distinctions between the mechanisms involved in the development of myogenic tone and the myogenic response have not been clearly defined. However, coronary artery myogenic tone is dependent on both Ca2+ entry through voltage –dependent Ca2+ channels and protein kinase C (PKC) activity. Impaired coronary myogenic tone has been observed in animal models of disease but the implications of these findings are currently uncertain.
Export Options
About this article
Cite this article as:
Izzard S. Ashley and Heagerty M. Anthony, Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease, Current Vascular Pharmacology 2014; 12 (6) . https://dx.doi.org/10.2174/15701611113116660150
DOI https://dx.doi.org/10.2174/15701611113116660150 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Mechanical Circulatory Support in Children
Current Cardiology Reviews Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Possibilities of Two-Dimensional Gel Electrophoresis in the Understanding of Human Disease
Current Proteomics Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology